




Cranberry capsules for acute radiation induced cystitis: The 










A thesis submitted for the degree of Bachelor of Radiation Therapy with Honours University of 








Acute cystitis is a common radiation side effect in prostate cancer patients undergoing radiation 
therapy treatment which results from radiation damage to the bladder. Acute cystitis symptoms can 
occur within weeks of starting radiation therapy treatment and symptoms include frequency, 
nocturia, haematuria, urgency, pain and a reduced capacity to store urine. Current standard of care 
focuses on symptom management and not on treating cystitis. Previous research had shown that the 
incidence of radiation cystitis and pain/burning was lower and urinary flow stronger in men taking 
daily cranberry capsules, compared with men taking placebo capsules. The aim of the current study 
was to validate these findings in a 100 patient multicentre stage III double blinded randomized 
controlled clinical trial. Here, I present the analysis of data collected from the Kathleen Kilgour 
Centre (KKC) between January 2018 and January 2019. 
Prostate cancer patients were randomised to take either 2 cranberry capsules containing 72mg of 
proanthocyanidins or 2 placebo capsules per day; these capsules were indistinguishable from each 
other. The capsules were taken daily starting on day 1 of radiation treatment and finishing two 
weeks after completion of radiation treatment. Three assessment scales were used measure the 
severity of acute radiation induced cystitis on day 1 of radiation treatment and once weekly after 
that until 2 weeks after completion of radiation treatment. Two of the scales are validated (the 
Modified Radiation Therapy and Oncology Group Scores and Interstitial Cystitis Symptom/Problem 
Scores) and one novel scale (Radiation Induced Cystitis Assessment Scale) was used to assess acute 
radiation induced cystitis. Participants filled out the Interstitial Cystitis Symptom/Problem Scores and 
the Radiation Induced Cystitis Assessment Scale themselves with the research radiation therapist 
(the author of this thesis) completing the Modified Radiation Therapy and Oncology Group Scores. 
These assessment scales included items on severity and frequency of symptoms as well as the 
impact of these symptoms on daily life for participants. 
Between December 2016 and February 2019, 34 men were recruited, and 33 men completed the 
trial (16 men in the cranberry arm and 17 in the placebo arm). This thesis reports on those that were 
recruited during enrolment of BRT Hons. A total of 19 men were recruited between January 2018 
and January 2019 (9 men in cranberry arm and 10 men in the placebo arm). There was no 
statistically significant difference between the severity of cystitis symptoms of patients who took 
cranberry capsules compared with patients who took placebo capsules, using any of the cystitis 
severity scales.  
Prostate cancer can lead to cystitis-like symptoms; therefore, it was anticipated that some men 
would present with these symptoms at baseline. Randomisation evenly distributed these men with 
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baseline symptoms between the cranberry and placebo arms therefore minimising any potential 
confounding of the results. To further ensure that the baseline symptoms did not confound the 
results, the maximum score minus the baseline score was determined and used in the statistical 
analysis. This allowed for the assessment of any worsening of cystitis symptoms as participants went 
through their radiation treatment. Therefore, the results will most accurately depict any effect 
cranberry capsules might have on the change in the severity of cystitis that the participants 
experience as they undergo radiation therapy treatment. 
Participants were allocated to one of three treatment regimens; a conventional regimen of 74Gy in 
37 fractions, a hypofractionated CHHiP regimen of 60Gy in 20 fractions, or the prostate bed regimen 
of 66Gy in 33 fractions. A lower total dose or a higher dose per fraction could affect cystitis severity. 
Randomisation between these three treatment regimens was stratified to minimise the confounding 
that the different treatment regimens could have on any potential differences in cystitis severity 
between men taking cranberry or placebo capsules. 
The placebo capsules used in this study contained red beetroot powder to make them 
indistinguishable from the cranberry capsules. This aided in successfully blinding the participants 
from visually assessing and knowing if they were on the cranberry or placebo capsules. However, 
beetroot contains antioxidants such as betalains, which also have anti-inflammatory properties. Both 
cranberry and placebo capsules were tested and compared to cranberry capsules, the placebo 
capsules had very low anti-inflammatory activity and no antioxidant activity. Therefore, the placebo 
capsules could be used in this trial as true inactive placebos. 
Participants are required to have a full bladder daily for their radiation therapy treatment. A full 
bladder reduces the irradiated volume of the bladder, therefore reducing the severity of the side 
effects. The bladder volumes and bladder doses received were similar between the cranberry and 
placebo arms and were not likely to confound the results of this study. Bladder volume is likely to be 
inconsistent from day to day and participants’ bladder volumes were checked daily on cone beam CT 
and participants were encouraged to hydrate to fill their bladder as full as when they did their 
planning CT scan. Daily variation in bladder volume is a potential unavoidable confounder in the 
study. 
In conclusion, this study found that cranberry capsules were not superior to capsules containing 
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CHAPTER 1. Introduction 
Prostate cancer is the most commonly diagnosed malignancy in men in New Zealand, with radiation 
therapy as a routine treatment modality. Radiation damage to the bladder, resulting in acute 
radiation cystitis, is a universal side effect in many men. Current standard of care focuses on 
symptom management and not on treating cystitis. Symptoms of cystitis include frequency, 
nocturia, haematuria, urgency, pain and a reduced capacity to store urine (1). Possible preventative 
and new treatment options need to be identified.  A previous pilot study in Dunedin Hospital 
showed that standardized cranberry capsules were better than placebo capsules in managing some 
symptoms of acute radiation cystitis in prostate cancer patients.  The current project is part of a 
multicentre stage III clinical trial which aims to validate the results of the pilot study in 100 prostate 
cancer patients who receive radiation treatment. This thesis analyses the results of 19 prostate 
cancer patients treated with radiation therapy in Tauranga between January 2018 and January 2019, 
as part of the BRT (honours) degree.  
This introductory chapter will give an overview of prostate cancer and its treatments, the effect of 
radiation on cancer tissue and normal tissues such as the bladder and urethra. Finally, current 
strategies for prevention and management of radiation cystitis will be discussed; leading to the 
rationale for the current study, its aims and objectives. 
1.1. Prostate Cancer  
Over 3000 men in New Zealand are diagnosed with adenocarcinoma of the prostate gland each year, 
making prostate cancer the most common diagnosis for men in New Zealand ahead of skin cancer 
(2). Many of these men are aged between 45 and 74, being diagnosed under 44 years old is rare. 
Although generally not considered an aggressive form of cancer,  more than 660 men die each year 
from prostate cancer making it the third most common cause of cancer related death in men, after 
lung and colon cancer (3). Both radiation therapy and surgery are considered first line radical 
treatment options, with androgen deprivation therapy often used in combination with radiation 
therapy.  
1.1.1 Location of the Prostate Gland 
The prostate is located anterior to the rectum, inferior to the urinary bladder, posterior to the pubic 
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Figure 1. Diagram showing location of the Prostate Gland (reproduced with permission from Terese 
Winslow (4)). 
 
1.1.2 Staging of Prostate Cancer 
Pathological staging requires biopsies of the prostate gland and pelvic lymph node dissection (5). 
Tumour/Node/Metastasis (T/N/M) staging considers the size and extent of the tumour, disease in 
any  regional lymph nodes and the presence of distant metastases (5). T/N/M staging can be 
complemented through clinical findings such a digital rectal examination or an elevated prostate 
specific antigen (PSA) level (6). The T category indicates how much of the prostate is invaded by the 
cancer with T1 being 5% or less of the resected tissue, T2 is palpable but confined within the 
prostate. T3 indicates extracapsular extension and T4 indicates that the tumour had invaded 
adjacent structures (5).  
1.1.3 Grading 
Tumours are graded using the Gleason Scoring System, the Gleason score is based on the sum of the 
two most common histological patterns, with the lower the number the more differentiated and less 
aggressive histology (7). In general, a Gleason score of 2-4 indicates well differentiated histology, 5-7 
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moderate and 8-10 poor differentiation. A low Gleason Score correlates with low pathological 
staging and increased survival (7). 
1.1.4 PSA level at the time of diagnosis 
PSA is an enzyme secreted by the epithelial cells of the prostate gland. PSA liquefies semen to allow 
sperm to move freely; it also liquefies cervical mucous, allowing the sperm to enter the uterus. Low 
levels of PSA (<0.2ng/mL) are present in the serum of healthy men. An increase in PSA levels 
indicates an increase in PSA excretion, which can indicate a benign (prostatitis or benign prostatic 
hyperplasia) or malignant disease (prostate cancer) (8). In individual cancer patients, regular PSA 
tests can give an indication of how well a treatment is working and whether or not remission is 
achieved or maintained. In a national screening context, PSA testing can detect significantly more 
tumours compared to a digital rectal examination (9). 
1.1.5 Prognosis 
The American Joint Committee on Cancer (AJCC) extensively reviewed the evidence behind staging, 
grading and molecular indicators as prognostic factors for all cancers and recently released the 
eighth edition of their Cancer Staging Manual (5). For Prostate Cancer this has meant that T/N/M 
stage, Gleason grade score and PSA level are all included to determine the prognostic stage group 
(8). Patients who are diagnosed when they are younger than 60 years old, have early onset prostate 
cancer. These patients have a distinct clinicopathological phenotype which is more aggressive and 
associated with a poorer prognosis than those who are diagnosed when they are older than 60 years 
old (10). 
1.2 Treatment modalities 
There are a number of radical treatment options with curative intent for men with prostate cancer;  
surgery, radiation therapy, androgen deprivation and cytotoxic chemotherapy (11). The elected 
treatment modality depends on multiple factors such as age, staging and grade of their cancer as 
well as lifestyle and the patient’s personal choice (11).  
1.2.1 Surgery 
Radical prostatectomy involves removing the prostate with an adequate margin of uninvolved 
tissue; it may mean that the seminal vesicles are removed as well (12).  Surgery is best suited for 
medically fit, younger patients whose cancer is contained within the prostate gland. The technique 
of the radical prostatectomy has improved in the last decade. This has resulted in fewer side effects 
as well as improving tumour control (12). Radical prostatectomy can still result in several side 
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effects, such as, urinary incontinence, erectile dysfunction, and blood loss. These side effects are 
caused by damage to the local nervous plexus as well as the arterial blood supply and venous 
drainage during the removal of the prostate (13). The level of distress caused depends on the 
severity of these side effects and their impact on the patient’s quality of life. Men who have 
undergone a radical prostatectomy experience more distress from decreased sexual ability, urinary 
incontinence and dysfunction compared with men who have undergone watchful waiting (12).  
1.2.2 Androgen deprivation therapy (ADT) 
ADT is used to improve the overall survival of high and intermediate risk prostate cancer. It is often 
used to shrink the tumour prior to other treatment modalities (14). All prostate cancers start off as 
hormone dependant, needing testosterone for growth and progression. ADT deprives the tumour of 
testosterone and is a key part in treatment of prostate cancer. However, all prostate cancers 
eventually become resistant to androgen deprivation (castrate resistant prostate cancer) and have 
limited further treatment options (15). A trial by D’Amico et al involving 206 men in Massachusetts, 
has shown that using 6 months of neo-adjuvant hormone therapy improved prostate cancer specific 
survival by reducing distant spread of disease (16). ADT induces testosterone deficiency and this has 
been shown to lead to several feminisation-related side effects including psychological and 
musculoskeletal changes (17). ADT leads to decreased bone mineral density which can increase the 
risk of fractures in patients (18). Patients report a decrease in physical function, poorer sexual 
function, hot flashes, fatigue, and breast tenderness as well as poorer emotional well-being (18). 
Even though these symptoms mostly disappear after ADT is stopped, they significantly decrease 
global quality of life for patients undergoing ADT. 
1.2.3 Radiation therapy 
The two types of radiation therapy used to treat prostate cancer, either as a monotherapy or 
combined, are brachytherapy and external beam radiation therapy (EBRT). Brachytherapy is very 
invasive and involves inserting a live radioactive source into the prostate. Low dose rate (LDR) 
brachytherapy consists of multiple radioactive seeds that are permanently implanted in the 
prostate, and deliver the dose over a relatively long time (19). High dose rate (HDR) brachytherapy 
delivers the dose at a high intensity by inserting a number of hollow needles containing a high 
intensity radioactive source through the perineum into the prostate for a short period of time (19). 
HDR can be delivered in one or two sessions on the same day 6 hours apart (19). Brachytherapy is 




EBRT is the most common form of radiation therapy as it is less invasive and can be used on patients 
that are older, have co-morbidities, and whose cancer has spread beyond the prostate.  
The current standard of delivery for prostate EBRT in New Zealand is IMRT (Intensity Modulated 
Radiation Therapy) or VMAT (Volumetric Modulated Arc Therapy). Both delivery techniques vary the 
intensity of multiple beams across the treatment field, resulting in dose escalation to the tumour 
and a steep dose fall off to the surrounding normal tissues compared to 3DCRT (3Dimensional 
Conformal Radiation Therapy) (20).  IMRT modulates the dose distribution by moving the multi leaf 
collimator (MLC) leaves across the tumour volume. The modulation within a single IMRT beam will 
compensate for the hot and cold areas that naturally occur in the dose distribution across a tumour 
volume. IMRT uses multiple beams in one plan to deliver a high degree of modulation within each 
beam. This allows for increased conformity of high dose to the tumour volume compared to the 
more conventional 3DCRT technique (20). During VMAT the gantry of the linear accelerator rotates 
in an arc whilst modulating the dose at different positions. Both IMRT and VMAT decrease the dose 
to normal tissues directly adjacent to the tumour but increase the total volume of normal tissues 
receiving low doses of radiation, resulting in better tumour control and less severe side effects (20).  
Radiation affects all living tissue in the same way. Ionising radiation kills both normal and cancer 
cells primarily via DNA damage. HDR brachytherapy, is likely to cause more intense side effects that 
occur sooner compared with EBRT or LDR brachytherapy due to the increased rate of radiation 
delivered to the normal tissue (11). Acute side effects are self-limiting and occur up to 3 months 
after radiation therapy. However, chronic or late side effects occur 3-6 months or even years after 
radiation therapy (21). Acute radiation-induced side effects for prostate cancer include acute 
radiation-induced cystitis of the bladder and acute radiation induced proctitis of the rectum. 
Increasing urgency and frequency of emptying both the bladder and bowel may cause distress for 
the patient and decrease their quality of life (21,22).  
Proctitis is the acute side effect of irradiating the rectum; symptoms include rectal discomfort, 
diarrhoea and occasionally rectal bleeding (21). Acute radiation induced cystitis is the acute bladder 
side effect experienced by radiation therapy patients. These symptoms include increased frequency, 
urgency, pain whilst urinating and occasionally blood in the urine (22).  External beam radiation 
therapy and brachytherapy cause late or long-term side effects which also need to be considered for 
the patient (21). Late toxicity of the rectum includes persistent proctitis, rectal bleeding and 
ulceration (21). Late toxicity of the bladder includes urgency and frequency as well as urethral 
stricture for a small number of patients (22). Impotency has also been noted as a long term side 
effect in patients who have received radiation therapy (11). Advanced treatment techniques, such as 
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IMRT and VMAT aim to reduce both the acute and late toxicities while maintaining tumour control 
(12). All toxicities have an ongoing impact on a patient’s quality of life, and it is important for these 
toxicities to be managed to improve the patient’s quality of life after treatment.  
1.3 Acute Radiation Induced Cystitis 
Radiation will cause damage to both normal and cancerous tissues. For many cancers the dose 
required for tumour control is limited by the dose that normal tissue can absorb before permanent 
injury occurs (23). The uncertainty in tumour delineation, organ motion and daily variation in patient 
positioning provide further challenges in delivering a lethal dose to the tumour while minimising 
normal tissue damage. To compensate for those uncertainties, margins are added to the clinical 
target volume (CTV) to create a planning target volume (PTV). The CTV is the volume of tissue where 
disease is likely to have spread microscopically. For prostate cancers the CTV will be the whole 
prostate and may include the seminal vesicles. The PTV aids in minimising the risk of missing the 
tumour, however, the PTV also extends into normal tissues such as the bladder and rectum. 
Therefore, the total dose that can be delivered for tumour control is limited by the dose that causes 
toxicity in those organs. The advancement in planning and treatment techniques allows for dose to 
be manipulated so that the maximal dose is delivered to the PTV whilst the dose to adjacent organs 
is minimised (23). Even so, damage to the bladder and rectum is unavoidable and the patient will 
experience a range of acute and chronic toxicities to some extent.  
When radiation penetrates any cell, the energy transfer causes either direct or indirect ionizations. 
Indirect ionizations involve the radiolysis or splitting of water, creating hydroxyl radicals (1). These 
unstable highly aggressive free radicals will react with and damage important macromolecules such 
as DNA (24). Direct ionizations also cause damage directly to the cell’s DNA or other important 
macromolecules. Damage to the cell’s DNA, especially if it is a double strand break, is the most likely 
cause of cell death (24).  
Cells have several cell cycle checkpoints to control progression through each stage of the cell cycle. 
In response to ionising radiation, cells need to first sense that their DNA has sustained damage and 
then halt progression through the cell cycle through the different cell cycle check points positioned 
at different points in the cell cycle. Halting the cell cycle is followed by DNA repair when successful, 
the cell cycle resumes  (25). There are several DNA repair pathways, some are specific for single 
stranded breaks, base damage and some for double stranded breaks, which are the most difficult 
and time consuming to repair, and most likely to kill the cell. 
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Although ionising radiation causes the same level of damage to normal and cancer cells, the 
effectiveness of their response to this damage differs. Cancer cells have multiple mutations in genes 
that govern one or more checkpoints, sense DNA damage and/or in damage repair. As a result, 
cancer cells that are not killed outright keep on dividing with damaged DNA making them more and 
more genetically unstable and picking up more mutations (25,26). There are several other factors 
that contribute to radiation sensitivity; one of those is the availability of oxygen. In the absence of 
oxygen, which is likely in larger tumours, radiation therapy is 3-4 times less efficient (26). 
1.3.1 Anatomy of the urinary bladder wall 
To understand the effect of radiation damage on bladder wall cells, the anatomy of the bladder wall 
needs to be taken into consideration (see Figure 2). The bladder wall is made up of multiple layers. 
From deep to superficial there are the muscular, submucosal, and mucosal layers (27).  
 
Figure 2. Illustration showing the anatomy and tissues layers of the bladder wall (reproduced with 
permission from SEER training (28)) 
 
The deepest layer of the bladder wall, the muscularis contains inner longitudinal, middle circular and 
outer longitudinal smooth muscle. Contractions of the circular detrusor muscle compresses the 
bladder which allows for the contents to be expelled via the urethra. The submucosa layer is made 
up of the lamina propria which consists of an extracellular matrix composed of several cell types as 
well as nerve endings (27).  The mucosa consists of highly specialised transitional epithelium 
(urothelium), made up of basal cells that are in contact with the basement membrane, several layers 
of intermediate cells and a single layer of large umbrella cells (29). Basal cells  serve as stem cells, 
precursors to other cell layers (27). Basal cells have an estimated half-life of 3 to 6 months before 
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they differentiate into intermediate cells and then into the larger umbrella cells. The intermediate 
cells are pyriform in shape and sit on top of the basal cells and can be anywhere from a single layer 
to multiple cell layers thick. Umbrella cells are specialised as they maintain an impermeable barrier 
even as the bladder fills and empties (30). The umbrella cells (see Figure 3) form a tight barrier that 
allows for urine to be retained while preventing unregulated movement of water, ions, solutes and 
macromolecules into the underlying tissue. Umbrella cells are long lived cells, but they will 
regenerate quickly if the urothelium is damaged (30). The quick regeneration of the umbrella cells as 
well as other cells in the mucosal layer, indicates that any damage sustained by radiation will be 
noticeable within a few weeks in the form of acute radiation-induced cystitis (1).  
 
 
Figure 3. Section through of the cellular layers of the bladder wall (reproduced with permission of 
Human Protein Atlas (31)) 
 
1.3.2 Symptoms of acute radiation induced cystitis 
The symptoms of acute radiation cystitis are comparable to those of infectious cystitis caused by a 
bacterial infection or interstitial cystitis, a form of sterile inflammatory cystitis. These symptoms 
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include frequency, nocturia, haematuria, urgency, pain and a reduced capacity to store urine (1). 
Acute symptoms of radiation cystitis are experienced by patients as they undergo radiation therapy, 
whereas late symptoms occur months to years after treatment. Acute symptoms largely self-resolve 
several weeks after the patient has finished treatment (22).  
Acute radiation cystitis is due to the damage to the urothelium thus compromising the integrity of 
this protective barrier. Irritation of the underlying submucosa and muscularis by acidic urine 
containing a number of enzymes and other irritants causes a non-infectious inflammatory response 
(1).  
Late or chronic radiation cystitis is caused by the damage to the deeper layers in the bladder which 
have slower regenerating cells. Radiation damage, resulting in fibrosis, to the smooth muscle in the 
bladder presents as reduced bladder capacity in patients which can impact on a patient’s frequency 
and urgency. Damage to the vasculature is associated with haematuria but it can also give rise to 
haemorrhaging, hypoxia and endarteritis (22).  
The symptoms from acute radiation induced cystitis, particularly if they are severe, can significantly 
compromise patient quality of life for a number of reasons (32).  Urgency and increased frequency 
during the day interfere with normal day to day activities such as working, exercising and socialising 
causing anxiety and social isolation.  
Nocturia is an increase in urinary frequency at night (33) and causes sleep disturbances. This means 
patients may be too tired to follow their normal routines, causing problems with work and social 
isolation (34).  
Acute radiation induced cystitis can also affect  personal relationships which all add to the increased 
anxiety, poor self-esteem and poor quality of life (32). 
It is important that medical practitioners appreciate the large impact that radiation induced cystitis 
can have on patient wellbeing. Radiation induced cystitis is often delayed in diagnosis due to the 
difficulties in clearly diagnosing acute cystitis as well as any possible delay in the patient seeking help 
(32). Adequately diagnosing and treating cystitis especially acute cystitis from radiation therapy 
treatment will help improve a patient’s quality of life and self-esteem. 
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1.4 Radiation Cystitis Assessments  
1.4.1 RTOG 
There are several different scoring systems for measuring the severity of acute radiation cystitis. The 
most common scoring system is the Radiation Therapy Oncology Group (RTOG) acute morbidity 
grading system created in the 1980s in addition to their late effects grading system (35). RTOG 
separates toxicities into 5 grades (see Table 1), with 0 meaning no effects and 5 meaning extremely 
severe effects leading to death. RTOG grades 1 and 2 are classified as minor and moderate toxicities 
and grades 3-5 are major toxicities. Each grade contains several different symptoms which makes it 
hard to determine from the grade which symptoms the patient is suffering from. In addition, RTOG is 
not very sensitive when determining differences in symptom severity in the moderate range (36,37).  
 
Table 1. Assessment of severity of radiation induced cystitis: RTOG (35) 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 










nocturia that is 
less frequent 
































The National Cancer Institute created the Common Toxicity Criteria (CTC) in 1997 to improve clarity 
and consistency in scoring acute radiation side effects. CTC is more comprehensive as it 
encompasses additional toxicities and divides them into separate grades, rather than combining 
them in a single grade. The CTC is updated regularly - in 2006 CTC was renamed the Common 
Terminology Criteria for Adverse Events (CTCAE) and in 2017 version 5 of CTCAE was released (38). 
CTCAE includes a variety of adverse events and is not limited to radiation side effects. The severity 
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scales are very similar to those of RTOG and therefore this scale is no more sensitive than RTOG for 
determining small changes in moderate toxicities (36) (see Table 2).  
In addition to a lack of sensitivity in measuring symptom severity differences within the moderate 
spectrum, neither RTOG or CTCAE measure the impact of the various toxicities on the patient’s 
health-related quality of life (HRQoL). There are several other scoring systems that measure function 
and symptoms but not HRQoL; these include the Incontinence Symptom Severity Index (39), the 
University California Los Angeles Prostate Cancer Index (40) and American Urological Association 
Symptom Index (41). 
Table 2. Assessment of severity of radiation induced cystitis: CTCAE version 5 Renal/Urinary Part (36) 
Adverse Event Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 


















Hematuria  none microscopic only intermittent gross 
bleeding, no clots 
persistent gross 






or necrosis or 
deep bladder 
ulceration  




no control (in the 
absence of fistula) 
n/a 
Urinary frequency/urgency  normal increase in 
frequency or 
nocturia up to 2 
x normal 
increase >2 x 
normal but 
<hourly 
hourly or more 
with urgency, or 
requiring catheter 
n/a 
Urinary retention  normal hesitancy or 




















period for <6 








tube, urethrotomy   
bladder 
rupture 
Urine colour normal asymptomatic 
change in urine 
color 
   
1.4.3 EPIC 
An increase in treatment options and ongoing refinement in radiation therapy delivery for prostate 
cancer has increased the numbers of patients surviving for many years post treatment (42). 
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Reviewing the patient holistically means that the assessment of side effects needs to include their 
effects on patient HRQoL. One scoring system that takes both function/symptoms, and HRQoL into 
account is the Expanded Prostate Cancer Index Composite (EPIC). EPIC was developed in 2000 from 
the University of California-Los Angeles Prostate Cancer Index. EPIC is a very comprehensive scaling 
system and includes side effects from surgical intervention, external beam radiation therapy, 
brachytherapy, and hormone therapy. EPIC is divided into five domains: urinary incontinence, 
urinary irritative/obstructive, bowel, sexual, and hormonal domains. Each domain contains both 
functional scores as well as scores that measure how much of an impact a symptom has on HRQoL 
(43).  
In contrast to RTOG and CTCAE, EPIC is scored by patients and contains 50 items for urinary, bowel, 
sexual and hormonal symptoms using Likert scales. The urinary domain on its own has 12 items. 
Each of the five domains have been tested and showed strong internal consistency and good test 
retest reliability (44,45).  All domains were validated separately and can be used independently (43). 
EPIC is unique in that it uses an algorithm to transform multiple LIKERT scores into a HRQoL score (1-
100%) (43). EPIC is used to specifically measure the impact of treatment of HRQoL and not to 

















Table 3. Assessment of severity of radiation induced cystitis: EPIC Urinary Domain (46)  
Adverse Event  
How often have you had pain or 
burning with urination? 
0 1 2 3 4 
Rarely or 
never 
About once a 
week 
More than 
once a week 
About once a 
day 
More than 
once a day 
How often have you urinated blood? 0 1 2 3 4 
Rarely or 
never 
About once a 
week 
More than 
once a week 
About once a 
day 
More than 
once a day 
How often have you taken URAL to 
alleviate your cystitis symptoms? 
0 1 2 3 4 
Rarely or 
never 
About once a 
week 
More than 
once a week 
About once a 
day 
More than 
once a day 
How often have you leaked urine? 0 1 2 3 4 
Rarely or 
never 
About once a 
week 
More than 
once a week 
About once a 
day 
More than 
once a day 
Which of the following best describes 
your urinary control? 
0 1 2 3  







How many pads or liners per day did 
you use to control leakage? 
0 1 2 3  
No pads 1 pad 2 pads 3 or more 
pads 
 
Adverse Event  
Overall, how much of a problem has 
your urinary function been to you?  








Which of the following best describes 
your urinary control? 








How many pads or adult diapers per 
do have you been using for urinary 
leakage? 








How big a problem, if any, has urinary 
dripping or leakage been for you? 








How big a problem, if any has each of 
the following been for you? 
a. Pain or burning with urinary 
b. Weak urine 
steam/incomplete bladder 
emptying 
c. Need to urinate frequently  








1.4.4. Interstitial Cystitis Symptom and Problem Scores 
Interstitial cystitis presents with similar symptoms to radiation induced cystitis. O’Leary et al created 
the Interstitial Cystitis Symptom and Problem Index (IC) to evaluate symptoms and their impact on 
HRQoL (47). IC has separate grades for each symptom and the impact each symptom has on HRQoL 
and is more sensitive to changes in moderate cystitis symptoms compared with RTOG and CTCAE. 
Although IC is designed to be self-administered it is not intended for stand-alone use and is 
recommended to be used in combination with other measures (47). This is because it was designed 
to capture the most important interstitial cystitis symptoms and therefore may be not be as 





Table 4. Assessment of severity of interstitial cystitis: ICS/P (47) 
IC Symptom scale (between 0 and 20) 
How often have you experienced 
pain/burning in your bladder? 
0 1 2 3 4 5 
Not at all A few times Fairly often Often Usually 
Almost 
always 
How often have you felt a strong 
need to urinate with little or no 
warning? 
0 1 2 3 4 5 
Not at all 
Less than 1 










How often have you had to urinate 
less than 2h after you finished 
urination? 
0 1 2 3 4 5 
Not at all 
Less than 1 










How many times did you typically 
have to get up in the night to 
urinate? 
0 1 2 3 4 5 
none 1x 2x 3x 4x 5x or more 
IC Problem Scores (between 0 and 16) 
How much has each of the following been a 








Burning/pain 0 1 2 3 4 
Having to urinate with little warning 0 1 2 3 4 
Having to urinate again within 2 hours  0 1 2 3 4 
Having to get up in the night to urinate 0 1 2 3 4 
1.4.5. RICAS 
Radiation-Induced Cystitis Assessment Scale (RICAS) for non-haemorrhagic cystitis is a new and as 
yet unvalidated scoring system that is modelled on the IC symptoms and problem scales and the 
EPIC Urinary Domain. RICAS was designed by Dr Herst after completing the cranberry pilot study 
(37), which used aspects of EPIC to score cystitis severity. RICAS was specifically designed for 
prostate cancer patients undergoing radiation therapy and consists of Likert scales to measure both 
symptom severity and symptom impact on HRQoL and is filled in by the patient himself. RICAS 
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measures the severity and impact of individual symptoms and is likely to be more sensitive to small 
changes in severity when compared with RTOG and CTCAE.  
This current clinical trial uses three of the scoring systems mentioned above: modified RTOG (grades 
1-3), IC Symptoms/Problem, and RICAS. 
Table 5. Novel scale for the assessment of severity of radiation induced cystitis: RICAS. 
RICAS: Radiation-induced Cystitis Assessment Scale (between 0 and 45) 
A. Item Severity Score (total scores between 0 and 27) 
How often do you feel pain or 
burning when urinating? 
  
0 1 2 3 
never once a day > once a day every time 
How severe is this pain? 
  
0 1 2 3 
none mild moderate severe 
How often do you feel pain in 
your bladder? 
0 1 2 3 
never once a week > once a week every day 
How severe is this pain? 
0 1 2 3 
none mild moderate severe 
How often do you need to urinate 
during the day time frequency? 
  
0 1 2 3 
normal 1.5-2x normal fewer than hourly more often than hourly  
How often do you need to get up 
in the night to urinate? 
  
0 1 2 3 
1-2 times 3-4 times fewer than hourly more often than hourly 
How quickly do you need to 
urinate when you feel the urge? 
  
0 1 2 3 
normal 
must go within 
30 min 
must go within 15 
minutes 
must go within 5 min 
How would you describe your 
bladder control?  
  




frequent dribbling no control at all 
How would you describe the 
strength of your flow? 
  
0 1 2 3 
normal slightly weaker moderately weaker much  weaker 
B. Item Impact Score (total scores between 0 and 18) 
How much of an impact has each 
of the following had on your life? 
no impact small impact moderate impact large impact 
Frequency and severity of 
pain/burning  
0 1 2 3 
Number of times you needed to 
urinate during the day 
0 1 2 3 
Getting up at night to urinate 0 1 2 3 
The urgency with which you had 
to urinate 
0 1 2 3 
The amount of control you had 
over your bladder 
0 1 2 3 
The strength of your flow 0 1 2 3 
 
EPIC was not used in this trial because it was designed to give a HRQoL score rather than focus on 
individual symptoms. The previous pilot study showed that the phrasing of several questions was 
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interpreted differently by different patients (37). When measuring pain or burning, EPIC asks the 
patient the frequency it occurred at but not the severity. Therefore, patients who experienced pain 
or burning multiple times a day will grade their symptoms the same regardless of how severe their 
symptoms are. RICAS separates frequency and severity for pain and burning to better assess patient 
symptoms and the impact on the HRQoL. Urgency is a significant bother to many patients; however 
EPIC does not assess this whilst both IC and RICAS have questions to assess urgency and the impact it 
has on HRQoL. 
1.5 Management of Radiation Induced Cystitis 
Due to the physical proximity of the bladder to the prostate, acute radiation cystitis is an 
unavoidable side effect of radiation therapy to the prostate. Although IMRT and VMAT treatment 
techniques minimise dose to the bladder and rectum compared to the more traditional 3DCRT.  
Patients are required to have a full bladder during irradiation to ensure that a large proportion of the 
bladder is pushed out of the treatment field, thus minimising the severity of acute radiation cystitis 
(48).  
There is currently no cure for acute radiation cystitis and management consists of symptomatic relief 
to improve patient quality of life (49). The number of well-designed clinical studies that assess the 
efficacy of different management strategies is limited  and further rigorous research, involving 
double blinded randomized controlled clinical trials (RCTs), into new management techniques is 
needed (50).  The only management options that are currently used clinically for acute radiation 
cystitis are URAL, terazosin, oxybutynin and, if the cystitis is chronic and severe, the patient may 
undergo hyperbaric oxygen treatment.  
At the Kathleen Kilgour Centre, URAL sachets are used for symptomatic relief of acute radiation 
cystitis. URAL is a urinary alkalizer, which reduces bladder acidity thus providing relief from pain, 
burning and frequency. Other medications to relieve symptoms used at the Kathleen Kilgour Centre 
are oxybutynin and terazosin. Oxybutynin causes relaxation of the smooth muscle in the bladder 
which reduces detrusor instability therefore reducing urinary urgency and frequency of both 
voluntary urination as well as reducing incontinence (51).  Terazosin is an alpha-1-adrenoceptor 
blocking agent and also reduces frequency of urination and incontinence for patients with bladder 
overactivity or a bladder outlet obstruction (52). Other management techniques for acute radiation 
cystitis that have been trialled but are not currently used in clinical practice are grouped into 
systemic therapies and cranberry products. Intravesical therapies, hyperbaric oxygen, and 
interventional procedures are also used for management of chronic radiation cystitis. Details of 
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these trials are summarised in Table 6. Most research has investigated the management of chronic 
radiation cystitis where the radiation damage is to the muscularis. Acute systemic therapies 
predominantly provide symptomatic relief instead of managing the acute radiation cystitis.  
1.5.1. Intravesical instillation for Chronic Radiation Induced Cystitis 
Intravesical instillation is a localised therapy which involves weekly bladder instillations and has the 
advantage over systemic therapies that the side effects are localised to the bladder. Several types of 
intravesical instillation therapies have been trialled, including glycosaminoglycan (GAG), 
replenishment therapies such as chondroitin sulfate and hyaluronic acid, oxybutynin, botulinum 
toxin type A and Bacilli Calmette-Guerin (BCG). Of these, only oxybutynin is used in clinical practice. 
The glycosaminoglycan (GAG) layer of the bladder is a mucus layer located on the surface of the 
urothelium. GAG protects the underlying urothelium from urine irritants and contains both 
chondroitin sulfate and hyaluronic acid as components. Several studies have investigated the use of 
adding those components for the management of chronic cystitis. Shao et al (2012) conducted a 
small randomised trial of 36 patients, 14 females with cervical cancer and 22 men with prostate 
cancer, and found that hyaluronic acid was equally effective as hyperbaric oxygen in managing pain 
and urinary frequency (53). Gacci et al (2015) found that a combination of hyaluronic acid and 
chondroitin sulfate in 23 prostate cancer patients improved chronic cystitis symptoms specifically 
nocturia (54). Although promising, these results need to be extended and validated in RCTs 
comparing hyaluronic acid and chondroitin sulfate to standard practice and a placebo (55).  
Endoscopic bladder injection with botulinum toxin type A has been shown to inhibit detrusor muscle 
over-activity and supress inflammation. Only one small retrospective case study has been conducted 
with botulinum toxin in four prostate cancer patients and two women with cervical cancer. The 
study demonstrated an improvement in bladder capacity and a reduction in frequency (56). A larger, 
prospective study needs to be completed to further explore this method of management for chronic 
radiation cystitis (55).  
Overall, studies of various intravesical instillation therapies have generally been too small and have 
lacked rigour to draw meaningful conclusions about their efficacy in the management of chronic 
radiation cystitis. Dawson and Jamison (2007) conducted a Cochrane review of interventional studies 
for the management of interstitial cystitis (57). Their review included interventions such as lifestyle, 
oral medications, intravesical instillations as well as surgical intervention. From their review Bacilli 
Calmette-Guerin (BCG) and oxybutynin were found to be well tolerated and showed the most 
18 
 
promising evidence of their efficacy, nonetheless the authors did state that further randomised 
controlled clinical trials are needed to move this field forward. 
1.5.2. Hyperbaric oxygen therapy for Chronic Radiation Induced Cystitis 
Hyperbaric oxygen therapy causes hyperoxygenation of scarred submucosal tissues resulting in  
capillary growth in those tissues (49). Two recent studies investigated the use of hyperbaric oxygen 
therapy for management of chronic cystitis. Dellis et al found that hyperbaric oxygen therapy in 11 
cancer patients with an undisclosed type of cancer, was beneficial for patients experiencing chronic 
cystitis (58). Oscarsson et al (2013) found that 39 patients undergoing hyperbaric oxygen therapy to 
manage their chronic cystitis showed improved patient EPIC scores at both 6 and 12 month follow 
ups (59). The results from this study warrant testing of hyperbaric oxygen therapy in larger cohort 
studies or randomised controlled clinical trials. 
1.5.3. Interventional procedures for Chronic Radiation Induced Cystitis  
Interventional procedures include radiological or surgical management of chronic cystitis. Both 
options have been explored in a small number of case studies. Interventional radiology involves 
radiological embolization of vesical arteries which is a minimally invasive option. To date, no long 
term follow up with large cohorts has been conducted (49). Banerji et al (2015) retrospectively 
investigated surgical intervention for 28 cervical patients who underwent ileal urinary conduit 
diversion out of the 62 patients who developed grade 3 or 4 chronic cystitis. Those who underwent 
surgical intervention, particularly if it was early intervention, had fewer hospital admissions and 
increased quality of life with early return to normal activity (60). As with other management 
methods, further larger studies need to be conducted to confirm these results.  
1.5.4. Systemic therapies for Acute Radiation Induced Cystitis 
Radiation to the bladder causes inflammation of the mucosa and submucosa, systemic therapies are 
therefore aimed at reducing inflammation. Tetracholordecaoxide (TCDO/WF10) has been shown to 
decrease inflammatory conditions and promote healing (49). A large 102 patient randomised open 
label trial (61) and a small 30 patient, single arm trial (62) showed that TCDO/WF10 decreased the 
need for antispasmodics and reduced recurrence of haematuria and dysuria. However, this drug is 
not currently licenced for the management of acute radiation induced cystitis and randomised 
controlled clinical trials are needed to validate these findings before it will be considered for use 
clinically. A small nonrandomised, uncontrolled and unblinded study investigated the use of 
flavoxate hydrochloride for the management of urinary tract symptoms. The 34 participants on the 
trial who took 1200mg per day showed improvement in  urgency and bladder capacity compared to 
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those who took 600mg per day (63). One small case study with 5 patients investigated whether 
conjugated oestrogen improved acute radiation cystitis symptoms. All 5 patients showed a decrease 
in haematuria however 2 patients received different dosages of conjugated oestrogen compared 
with the other 3 patients (64). These studies on flavoxate hydrochloride and conjugated oestrogen 
should be considered feasibility studies because of the small number of participants and the lack of 
randomising and blinding. Larger studies would be necessary to determine whether or not proper 
double blinded randomised controlled clinical trials are warranted. 
1.5.5. Cranberries for Acute Radiation Induced Cystitis 
Cranberries (vaccinium macrocarpon) have been promoted for the treatment of urinary tract 
infections for decades (65). A 2012 Cochrane review of 24 studies reported that cranberry products 
aid in treating and preventing recurrence of urinary tract infections, however this was not a 
statistically significant finding. The review also recommends using cranberry tablets instead of 
cranberry juice as the juice may be unacceptable to consume long term, causing gastrointestinal side 
effects including nausea and diarrhoea (66). However, there are gaps in evidence-based research to 
support using cranberry products to prevent and manage infectious cystitis or acute radiation 
induced cystitis.   
Cranberry products, in particular the proanthocyanidins, prevent urinary tract infections by 
preventing adherence of bacteria (Escherichia coli) to the uroepithelial cells lining the bladder wall 
(67). However, literature and clinical studies show conflicting results with respect to the efficacy of 
cranberry products against urinary tract infections (68). Further rigorous trials are needed to confirm 
the efficacy of cranberry products in clinical use for infectious urinary tract infections in different 
cohorts (65). With respect to managing acute radiation cystitis only four studies to date have 
investigated the effectiveness of cranberry products with mixed results. 
Cowan et al (2012) investigated whether cranberry juice decreased urinary symptoms or the 
incidence of urinary tract infections during and immediately after radiation therapy (69). This was a 
double blinded, placebo-controlled trial which included 128 prostate cancer patients. The placebo 
juice was developed to look and taste like cranberry juice. Participants were required to drink one 
glass in the morning and one at night. Drinks were not standardised, and no details were given of 
proanthocyanidin (PAC) content. Recruitment was slower than anticipated as over half of potential 
participants were excluded from the study because they displayed urinary symptoms at baseline. 
Compliance was an issue, with only 32 patients drinking more than 16 litres during the trial period. 
Some patients reported a dislike of the taste as well as nausea while taking the juice. Cowan et al 
used CTCAE to weekly score side effects throughout radiation treatment and for two weeks after 
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treatment had finished. Due to poor compliance and low recruitment rate the small observed 
difference in the incidence of urinary symptoms and urinary tract infections in favour of the 
cranberry arm did not reach statistical significance (p=0.24).  
Campbell et al (2003) compared cranberry juice with apple juice for the management of urinary 
symptoms during radiation therapy (70). A total of 112 prostate cancer patients entered the study 
and patients were randomised to either the cranberry juice or the apple juice arm. They were 
required to drink 118ml of juice three times per day, totalling 354ml per day. Participants were 
asked to avoid other fruit juices but could otherwise eat a normal diet. The PAC content of the 
cranberry juice was not disclosed. This study used a modified International Prostate Symptom Score 
(IPSS) questionnaire to score participants symptoms. Patients completed a modified IPSS 
questionnaire twice a week throughout their treatment and for two weeks after. The quality of life 
portion of IPSS was removed as the wording of it was not felt appropriate for this trial. Return of the 
IPSS questionnaire in the two week post treatment follow up was poor therefore data was analysed 
both with and without this extended data collection with no significant difference in the results 
between arms. Overall this study does not show a significant difference in urinary symptoms 
between patients that took cranberry juice and those that took apple juice (p=0.76). 
Bonetta and Pierro (2012) investigated whether or not standardised cranberry tablets were more 
effective at reducing the risk of a urinary tract infection compared with standard treatment in 370 
patients undergoing radiation for prostate cancer (71). This study used standardised cranberry 
tablets instead of juice. Patients who were on the cranberry arm were required to take one tablet 
daily containing 60mg of PACs without food, there were no other dietary requirements for either 
arm. Patients in the control arm received normal standard of care, which was not detailed. Urinary 
tract symptoms were assessed weekly using the Boyarsky scale. Although this study showed that the 
cranberry tablets significantly decreased lower urinary tract symptoms (p<0.01), the limitations of 
this study need to be considered. Patients were not randomised, and it is unclear how patients were 
allocated to the different treatment arms; allocation bias may have contributed to the favourable 
outcome. Patients were not blinded and thus reporting bias cannot be excluded. No scores were 
taken after the completion of radiation treatment. Acute radiation therapy side effects tend to peak 
after treatment has finished therefore the post treatment scores would have provided valuable 
information.  
Hamilton et al (2015) investigated the efficacy of standardised cranberry capsules compared with 
placebo capsules for managing acute radiation cystitis symptoms in patients undergoing treatment 
for prostate cancer (37). This randomised double-blinded placebo-controlled trial recruited 41 men 
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which were randomised to the cranberry or the placebo arm. Participants took one capsule per day 
at breakfast throughout their treatment and for two weeks afterwards. Each cranberry capsule 
contained 72mg of PACs. The placebo capsules were designed to look the same as the cranberry 
capsules. Participants had their urinary symptoms scored at baseline as well as on a weekly basis 
including two weeks after treatment, using the urinary domain of the modified EPIC. This trial 
showed that cranberry capsules decreased the severity of acute radiation cystitis as evidenced by a 
statistically significant decrease in pain/burning (p=0.038), stronger urine stream (p=0.030), and 
using significantly fewer pads (p=0.042). These encouraging results need to be validated in a larger 
clinical trial, and that is the subject of this thesis.  
Although the manner in which cranberry products mediate urinary tract infections is well 
established; little is known about the mode of action of cranberry products in reducing acute 
radiation cystitis. Radiation damage is caused by cell death or injury due to DNA damage, caused 
predominately by free radicals. Cranberries contain polyphenols including flavonoids, anthocyanins 
and PACs, which are compounds known for their anti-oxidant properties. This makes cranberry 
products likely candidates for neutralising free radicals during radiation and thus lessening cystitis 
severity (72,73). The bioavailability of those compounds in the bloodstream is very poor, <1-5% of 
ingested dose in both rats and humans (74).  Therefore, it is unlikely that the antioxidants will get to 
the cancer to provide a protective effect. This poor bioavailability means that cranberry products are 
likely to rapidly accumulate in the bladder where they could provide relief from acute radiation 
cystitis through free radical scavenging.  
Current literature speculates that PACs may also reduce acute radiation cystitis through protection 
of the bladder lining by decreasing inflammation in other ways than through free radical scavenging 
(75). The transcription factor NF-kB plays a role in coordinating the inflammatory response. One 
study suggests that in healthy adult volunteers anthocyanins inhibit NF-kB activation (76). 
Dampening of NF-kB activation in white blood cells, located in the lamina propria, thus limiting the 
inflammatory response may result in decreasing the extent of inflammatory responses such as acute 








Table 6. Different interventions for the management of radiation cystitis  
Intervention Trial Patient number Measurements Basic outcomes 
Flavoxate 
hydrochloride 





Improved bladder capacity, volume and 
decreased urgency at capacity 
Conjugated 
oestrogen 
Lui et al 1990 5 Unknown  Improved haematuria 






Decreased bladder symptoms 
TDCO/WF10  
Veerasarn et al 2004 
100 women 




Improvement in haematuria, reduced 
antibiotics, reduced antispasmotics 
Veerasarn et al 2006 30  SOMA scale Improved haematuria 
Botulinum Toxin A. Chuang et al 2008 6 Unknown 





Shao et al 2011 36 
Visual analogue 
scale of pain 
Decreased frequency, pain, haematuria 








Oscarsson et al 2013 
34 prostate, 3 
rectal, 2 cervical 
cancer  
EPIC Decrease in cystitis symptoms 
Dellis et al 2014 11 RTOG/EORTC Decrease in bladder symptoms 




Increase in quality of life, decrease in 
hospital admissions 
Cranberry products  




No significant difference between the 
two arms 
Cowan et al (2012) 
128 cervix and 
bladder cancer 
CTCAE Decreased grade 3 cystitis 




Decrease in UTI incidence, decreased 
frequency, nocturia, urgency and 
improved urine flow 
Hamilton et al (2015) 41 EPIC 
Decreased pain, decreased 







1.6 Aims/objectives of study. 
Acute radiation cystitis is a common side effect of radiation therapy for prostate cancer with urinary 
symptoms such as frequency, urgency, haematuria and nocturia which compromises quality of life. 
Current best practice focuses on acute radiation cystitis symptom management. A previous pilot 
study showed standardized cranberry capsules were better than a placebo in preventing/managing 
aspects of acute radiation cystitis in prostate cancer patients.  This thesis analyses the results of 19 
prostate cancer patients treated with radiation therapy in Tauranga between January 2018 and 
January 2019, as part of a larger multicentre double blinded randomised controlled clinical trial. 
Aim  
To determine if standardized cranberry capsules are superior to placebo capsules in managing acute 
radiation cystitis in a sub-cohort of prostate cancer patients receiving radiation treatment, who are 
taking part in a larger multicentre double blinded randomised controlled clinical trial. 
Hypothesis  
The hypothesis is that cranberry capsules are superior to placebo capsules in decreasing the severity 
of acute radiation cystitis symptoms in prostate cancer patients receiving radiation treatment. 
Specific Objectives  
Superiority of cranberry capsules over placebo capsules in managing acute radiation cystitis will be 
determined by comparing the severity of acute radiation cystitis symptoms between patients who 
take cranberry capsules and those that take placebo capsules. Three different measuring scales will 
be used to achieve this: 
1. Modified RTOG 
2. Interstitial Cystitis Symptom/Problem Scale 







CHAPTER 2. Methodology 
The current study was part of a multi-centre phase 3, randomised double blinded placebo-controlled 
trial (RCT). This RCT compared the effect of cranberry capsules and placebo capsules on the severity 
of acute radiation induced cystitis in men receiving EBRT for prostate cancer.  
Cystitis was assessed using a modified Radiation Therapy Oncology Group Scale (35) (Table 1), an 
interstitial cystitis (IC) scale (47) (Table 4) as well as a new scale RICAS (Table 5). This honours thesis 
analyses the data from 19 patients from the Kathleen Kilgour Centre as part of the larger 104 patient 
trial. 
Ethical approval was gained from the Southern Health and Disability Ethics Committee (Protocol 
number 15/STH/217) (Appendix A) and from Medsafe (16/SCOTT/51) (Appendix B) and the trial was 
registered in the Australian New Zealand Clinical Trials Registry: ACTRN12615001311549. The trial 




Men were eligible if they were receiving radiation therapy to their prostate bed or prostate only and 
had not received previous pelvic radiation therapy. They had to be able to give informed consent, 
have a Karnofski score >70, not be allergic to cranberries or their products, not have a history of 
kidney stones, and not be on anti-coagulants (78). The Kathleen Kilgour Centre HDR brachytherapy 
patients were also excluded due to the chance that the HDR needles might pierce the bladder 
and/or the urethra and cause haematuria. The participants for this thesis started their radiation 
therapy within the thesis recruitment period, January 2018 to January 2019. 
2.2 Randomisation and Blinding 
Randomisation using computer-generated random numbers circumvents any potential confounding 
due to allocation bias. In this trial, participants were randomised to receive a bottle filled with either 
the cranberry capsules or placebo capsules. Prior to the trial, the Principle Investigator (Dr Patries 
Herst) randomised the bottles containing cranberry and placebo in a 1:1 ratio based on computer 
generated numbers provided by the University of Otago biostatistician. Bottles were designated with 
letters and numbers representing the trial arm and participant number. All bottles for the Kathleen 
Kilgour Centre were designated KKC; bottle KKCC01 was for the first patient on the CHHiP 
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fractionation of the trial, bottle KKCP01 was for the first conventional fractionation arm for prostate 
cancer and KKCB01 was for the first patient who received radiation to the prostate bed. 
The New Zealand Company Creative Energy LTD provided the standardised cranberry and placebo 
capsules. Bottles contained either 140 cranberry capsules (containing 36mg of PACs each) or 140 
placebo capsules containing silica, magnesium stearate, cellulose, beetroot powder and gelatin. 
Randomising patients to the different arms in this manner circumvents allocation bias, which was a 
potential confounder of the Bonetta and Pierro (2012) study (71). Blinding is also an important 
aspect of clinical trials because it accounts for the placebo effects, where patients feel better if they 
think they are getting the medication. It also prevents patient and researcher bias, where patients 
and researchers are potentially influenced by their knowledge of which type of capsules the patient 
is taking. This RCT was double-blinded, neither the participant, investigator, study management 
team, or clinical staff knew if the control or placebo was given to the participant. The placebo and 
cranberry capsules were indistinguishable from each other in both appearance and packaging. 
Unblinding occurred after all participants had completed the trial to enable data analysis. 
2.3 Description of Radiation Therapy Treatment 
Participants receiving treatment to the prostate were prescribed a dose of 74Gy in 37 fractions or 
the CHHiP trial dose of 60Gy in 20 fractions. Participants receiving radiation therapy to the prostate 
bed were prescribed a dose of 66Gy in 33 fractions. All patients received 6MV or 10MV photon 
beam IMRT or VMAT with a consistent planning technique. Treatment was delivered in the supine 
position in one or two arcs, or 7 fields. Participants were instructed to have a full bladder and empty 
bowels for their CT scan and then each day for treatment. To achieve this, participants emptied their 
bladder and bowels an hour before treatment then consumed three cups of water with no further 
voiding until after their CT or treatment. Daily Cone Beam CT scans were performed to assess 
prostate position plus, bowel and bladder status, as per standard department protocol.  
2.4 Trial Regimen 
Details of the trial regime and timeline are shown in Figure 4. 
The Radiation Oncologist identified which patients were likely to be suitable for the trial at the 
patient’s first specialist appointment. The Radiation Oncologist gave out the participant information 
sheet (Appendix C) for the patient to read and take home. The participant information sheet 
outlined the different aspects of the trial, that involvement is voluntary, access to their personal 
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health data during and after the trial and other considerations. Attached to the participant 
information sheet is the informed consent form.  
When the participant came in for their CT Planning appointment the Trial Radiation Therapist (TRT: 
the author) discussed the participant information sheet with the patient and ensured that they had a 
good understanding of what will happen during the trial and what is expected of them as 
participants.  
On their first day of radiation therapy the TRT discussed the trial with the patient again and ensured 
that all questions about the trial were answered. The TRT also made sure that the informed consent 
was signed. 
Participants were given their bottle of capsules on their first day of treatment and were told to take 
two capsules every day at breakfast, during treatment and for two weeks post treatment (nine 
weeks prostate bed, ten weeks prostate, 6 weeks CHHiP trial dose prostate arms). 
Participants were specifically told not to consume any foods, drinks or supplements containing 
berries including cranberries, blueberries, blackberries and blackcurrants and were to limit 
consumption of red grapes and red wine to 1 glass per night. 
Weekly, participants independently filled out the RICAS and IC questionnaires and met with the TRT 
or the radiation oncology nurses to fill out the modified RTOG assessment. 
 
Figure 4. Trial Regimen and Timeline 
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2.5 Radiation Cystitis Assessments 
A description of the various scores is given in Chapter 1 (Paragraphs 1.4.1, 1.4.4, 1.4.5.) 
Modified RTOG  
The validated urinary domain of the RTOG assessment tool was used for this trial (35) (Table 1). The 
RTOG Scoring Criteria used for the current trial was modified by removing grade 4-5 cystitis (life 
threatening and death respectively) because such severe cystitis is unlikely to be affected by 
cranberry capsules (Table 7). Items that are normally graded together under RTOG (pain, urgency, 
daytime and night time frequency) were graded separately for the current trial because this would 
allow us to determine which of these individual symptoms were present in the cohorts (Table 7). 
Table 7. Modified RTOG  
 Grade 0 Grade 1 Grade 2 Grade 3 




Pelvic pain bladder 
spasms frequent 
narcotics 









Normal 2x pre-treatment < once an hour Once an hour 
Night time 
frequency 
Normal 2x pre-treatment < once an hour Once an hour 
 
Interstitial Cystitis 
The O’Leary Interstitial Cystitis Symptom (ICS) and Interstitial Cystitis Problem (ICP) Scales are more 
sensitive than the modified RTOG questionnaire and also includes a patient impact component (47) 
(Table 4). The O’Leary ICS/ICP is validated (47) and distinguishes smaller differences in severity of 
cystitis than RTOG that may be clinically relevant. 
RICAS 
RICAS is a novel radiation cystitis assessment tool as it is modelled on both the RTOG and IC/ICP 
scales. RICAS also has both an item severity score component as well as an item impact score. This 
scoring sheet is more sensitive than RTOG but is also more pertinent to acute radiation induced 
cystitis than O’Leary’s ICS/ICP. 
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2.6 Adverse Reactions 
In case of a serious medical event requiring knowledge of whether the patient had been taking 
cranberry capsules, the treatment arm allocation would be provided by the Principal Investigator. 
The time, date, subject number and reason for obtaining any of these codes, and therefore breaking 
the blinding, would be documented in the study file. Unblinding would only be requested by the 
Investigator or other persons designated as sub-investigators. 
2.7 Statistical Consideration: Data Collection, Entry and Analysis 
RTOG, IC, RICAS scores and participant characteristics were entered into Excel work sheets, which 
were used to calculate averages, standard deviations and standard errors as reported in the results 
section. Scores were analysed with IMB SPSS Statistics version 25.0 Non-parametric Wilcoxon rank-
sum tests were used to determine if difference in the mean of the maximum less baseline scores of 
patients in the cranberry and placebo arms were statistically significant (p-value <0.05). 
Statistical considerations: sample size 
A total sample size for the larger stage III trial of 104 analysable patients is based on the previous 
pilot study in 41 men. The stage III RCT is powered to 80% to detect a statistically significant 
difference between cranberry and placebo arms (p<0.05) in the level of pain, extent of nocturia, and 
strength of stream. These patients were recruited at the Southern Blood and Cancer Centre in 
Dunedin, Kathleen Kilgour Centre in Tauranga and in Auckland Radiation Oncology in Auckland. The 
results discussed in this thesis are for patients that were recruited at the Kathleen Kilgour Centre in 
Tauranga during the BRT(Honours) period. 
Statistical considerations: stratification 
There were three different treatment prescriptions for this trial: 1) conventional: 74Gy in 37 
fractions, 2) CHHiP trial: 60Gy in 20 fractions, and 3) prostate bed: 66Gy in 33 fractions. It was likely 
that these different prescriptions would affect the severity of acute radiation cystitis, therefore 
separate randomisation sheets were used for each treatment prescription. This circumvents possible 
confounding by evenly distributing patients between arms for each treatment prescription. 
2.8 Funding 
The capsules were bought from the New Zealand Company Creative Energy LTD, with a University of 
Otago Research Grant. The Rouse Educational Trust aided in funding the cost of this thesis. The 
University of Otago, Wellington, paid the salary of Associate Professor Patries Herst (PI) and the 
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Kathleen Kilgour Centre Board paid the full salary of Vanessa Sword (Research Radiation Therapist 
and honours student). Salaries of radiation therapists and oncology nurses in Dunedin and Auckland 
























CHAPTER 3. Results 
The thesis analyses the data sets of 19 patients who received radiation therapy for prostate cancer 
in the Kathleen Kilgour Centre (KKC) between 10 January 2018 and 16 January 2019. Of these 19 
patients, nine men were randomised to the cranberry arm and ten men to the placebo arm. For the 
larger trial, a total of 33 eligible participants were enrolled at the KKC between 20 February 2017 
and 16 January 2019. Out of the 53 patients who were eligible for the trial at the KKC, 15 patients 
declined participation, four patients were missed because the oncologist did not mention the trial to 
the patient or to the author. A total of 34 men were randomised to control (n=17) and placebo arms 
(n=17); 14 of these men were recruited by the author before recruitment for this thesis commenced 
(see consort diagram in Figure 5). 
  
 











3.1 Patient Demographic Characteristics 
The demographic information for these cranberry and placebo cohorts is presented in Table 7. 
Table 8. Baseline demographics and clinical characteristics for each cohort.  
Characteristics 





Personal Construct    
Age  67 (55-73) 68 (52-78) 68 (52-78) 
    
Ethnicity     
        NZ European  8 (88.9%) 10 (100%) 18 (95%) 
        Maori/NZ European 1 (11.1%) 0 (0%) 1 (5%) 
    
Smoker    
        Never 2 (22.2%) 1 (10%) 3 (16%) 
        Past/Current  7 (77.8%) 9 (90%) 16 (84%) 
    
Alcohol    
        ≤ 1 standard drink/week  1 (11.1%) 2 (20%) 15 (75%) 
        ≥ 1 standard drink/week 8 (88.9%) 8 (80%) 5 (25%) 
Baseline cystitis symptoms    
        Yes 6 (66.7%) 7 (70%) 13 (68%) 
        No 3 (33.3%) 3 (30%) 6 (32%) 
Treatment Construct    
Treatment Site n (%)    
        Prostate 74Gy/37# 2 (22.2%) 0 (0%) 2 (10%) 
        Prostate CHiP 60Gy/20# 4 (44.4%) 7 (70%) 11 (58%) 
        Prostate Bed 66Gy/33# 3 (33.3%) 3 (30%) 6 (32%) 
    
Adjuvant Hormones Therapy  5(55.6%) 4 (40%) 9(47%) 
    
Planning Construct DVH    
Mean dose ± SD (Gy) 26.7 ± 13.7 24.3 ± 9.6 24.9 ± 11.1 
Minimum dose ± SD (Gy) 2.2 ± 2.0 1.6 ± 1.0 1.9 ± 1.5 
Maximum dose ± SD (Gy) 68.2 ± 5.8 64.4 ± 3.5 63.4 ± 14.0 
    
Total bladder volume  (cc) 314.5 ± 141.6 312.2 ± 111 305.2 ± 122.4 
 
3.2 Bladder Volumes 
Bladder filling is recommended as this can reduce bladder toxicities by decreasing the dose-volume 
load of the bladder (79). A participant with a fuller bladder, therefore, should experience less cystitis 
due to the reduction in the irradiated volume of the bladder. Dose volume histograms (DVH) were 
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obtained in trial patients using the planning software Monaco. Participant anatomy was contoured 
using the 3D helical planning CT scan. Information on the bladder volume (cc) was provided along 
with an overview of the maximum, minimum and average bladder dose across the IMRT or VMAT 
dosimetry plan (Table 8). 
The bladder volume and dose determined on the participant’s pre-treatment CT scan can only be 
used as an indicator of the bladder volume and therefore mean dose received across treatment. 
Daily cone beam CT scans captures the daily variation in bladder filling and positioning throughout a 
participant’s treatment  (79). The bladder filling data available from the daily CBCT’s was compiled 
(Appendix D). As participants were further along in their treatment regimen their capacity to achieve 
their bladder filling compared to their pre-treatment CT was reduced. This may be due to acute 
radiation induced cystitis. This reduction in bladder capacity may have compounded the severity of 
acute radiation induced cystitis as an increase in mean bladder dose would result in increased 
radiation damage to the bladder. 
However, the bladder doses and volumes between the placebo and cranberry arms were very similar 
and thus dose to the bladder was not a likely confounder in this trial (Table 8). 
3.3 Anti-inflammatory and antioxidant activity of cranberry and placebo capsules 
The placebo capsules for the current clinical trial contained red beetroot powder as a colouring 
agent to make the indistinguishable from cranberry capsules (Appendix E). Beetroot does not 
contain any anthocyanidins but they do contain betalains. Several studies have investigated the 
efficacy of betalains as an antioxidant to aid in reducing chronic inflammation processes (80,81). 
Betalains are thought to act as an antioxidant by scavenging free radical species and therefore 
protecting cells from oxidative stress (82,83) Betalains have also been suggested to dampen the 
inflammatory response by interrupting the inflammatory pathway and inhibiting the NF-kB response 
(84).  
Dr Patries Herst conducted anti-inflammatory and antioxidant assays to investigate the anti-
inflammatory and antioxidant effect of both the cranberry and placebo capsules. The results from 
these assays showed that the placebo capsules had a very low anti-inflammatory (IC50 = 99.0 µg/mL) 
and no antioxidant activity (IC50>1000 µg/mL) compared to cranberry capsules (IC50 = 5.5 µg/mL and 
57.5 µg/mL respectively) (for more detail see Appendix E). Therefore, the placebo capsules could be 
used as inactive placebos in this trial. Acidity tests showed that the contents of one cranberry 
capsule dissolved in deionized water was more acidic with a pH of 3.9 +/- 0.2 compared with the 
content of a placebo capsules with a pH of 6.3 +/- 0.3. 
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3.4 Effect of Cranberry and Placebo Capsules on Severity of Acute Radiation Induced 
Cystitis 
Patients presenting with cystitis symptoms at baseline 
Prostate cancer can present with cystitis-like symptoms. It was anticipated that several participants 
on the trial would present with some symptoms at baseline. If any participant scored at least two 2s 
for any item at baseline, this was defined as presenting with baseline cystitis symptoms. To 
accurately measure the effect of the cranberries on acute radiation induced cystitis, the scores that 
were reported were the maximum score minus the baseline scores to demonstrate any effects 
regardless of baseline urinary symptoms. An even division of participants with baseline symptoms 
was seen between the two arms with six men receiving cranberry capsules presenting with baseline 
symptoms and seven men receiving placebo capsules with baseline symptoms. This shows that 
baseline symptoms was not a likely confounder in this trial. 
Three scales were used for measuring the severity of radiation-cystitis: Radiation-Induced Cystitis 
Assessment scale (RICAS), Interstitial Cystitis Symptoms and Problem Scale (ICS/P) and modified 
RTOG.  
Radiation cystitis scores are presented in Table 9 for modified RTOG, in Table 10 for ICS/P and Table 
11 for RICAS. 
Both the severity of the acute radiation cystitis symptoms, as well as their effect on day to day life, 
was very similar between the two arms with any small differences statistically insignificant. 
 
Table 9. Modified RTOG scores for patients on the cranberry and placebo arms  
Maximum-baseline scores for each item Cranberry (n=9) Placebo (n=10)  
RTOG Ave SEM Range Ave SEM Range p value* 
Pain 0.67 0.13 0-1 0.50 0.13 0-1  0.66 
Urgency 0.89 0.15 0-2 0.70 0.17 0-2  0.66 
Day time frequency 1.33 0.22 0-3 1.10 0.14 0-2  0.78 
Night time frequency 1.00 0.13 0-2 0.60 0.21 0-3  0.16 






33-Table 10. ICS/P scores for patients on the cranberry and placebo arms 
Maximum-baseline scores for each item Cranberry (n=9) Placebo (n=10)  
IC Severity Ave SEM Range Ave SEM Range p value* 
How often have you experienced pain/burning in your 
bladder?  1.11 0.26 0-3 1.50 0.49 0-5  0.55 
How often have you felt a strong need to urinate with 
little or no warning? 1.89 0.36 0-5 0.90 0.22 0-3  0.27 
How often have you had to urinate less than 2h after 
you finished urination?  1.67 0.28 0-5 1.70 0.24 0-4  0.79 
How many times did you typically have to get up in the 
night to urinate? 1.33 0.18 0-5 1.30 0.26 1-5  0.74 
IC Problem            
Burning/pain?  0.67 0.18 0-2 0.60 0.24 0-3  0.86 
Having to urinate with little warning? 1.56 0.28 0-4 1.10 0.25 0-3  0.37 
Having to urinate again within 2 hours? 1.44 0.31 0-4 1.40 0.24 0-3  0.94 
Having to get up in the night to urinate? 1.56 0.22 0-3 0.90 0.22 0-3  0.16 
* Wilcoxon signed rank test 
 
Table 11. RICAS scores for patients on the cranberry and placebo arms  
Maximum-baseline scores for each item Cranberry (n=9) Placebo (n=10)  
RICAS Ave SEM Range Ave SEM Range p value * 
Severity             
How often do you feel pain and burning when urinating? 1.11 0.26 0-2 1.10 0.30 0-3  0.93 
How severe is this pain 0.78 0.21 0-2 0.80 0.20 0-2  0.76 
How often do you feel pain in your bladder? 1.11 0.29 0-3 1.10 0.34 0-3  0.67 
How severe is this pain? 0.67 0.18 0-2 0.70 0.21 0-2  0.75 
How often do you need to urinate during the day time 
frequency? 1.33 0.13 0-3 1.20 0.11 0-3  0.56 
How often do you need to get up in the night to urinate? 0.78 0.24 0-2 1.30 0.21 0-3  0.13 
How quickly do you need to urinate when you feel the 
urge? 1.00 0.28 0-3 1.00 0.24 0-3  0.73 
How would you describe your bladder control? 0.67 0.18 0-2 0.00 0.12 0-2  0.06 
How would you describe the strength of your flow? 0.89 0.15 0-3 0.80 0.26 0-3  0.86 
RICAS Impact    
Frequency and severity of pain/burning 0.33 0.18 0-2 0.40 0.17 0-2  0.78 
Number of times you needed to urinate during the day 0.44 0.28 0-3 0.70 0.31 0-3  0.40 
Getting up at night to urinate 0.78 0.30 0-3 0.70 0.29 0-3  0.89 
The urgency with which you had to urinate 0.89 0.20 0-3 0.90 0.30 0-3  0.76 
The amount of control you had over your bladder 0.33 0.25 0-3 0.40 0.13 0-2  0.74 
The strength of your flow 1.22 0.24 0-3 0.70 0.24 0-2  0.19 
*Wilcoxon signed rank test 
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3.5 Correlation between Radiation-Induced Cystitis Assessment Scale and O’Leary 
Interstitial Cystitis Severity and Problem Combined Scores 
Radiation-Induced Cystitis Assessment scale (RICAS) is a novel score which has not been validated as 
a measurement tool. In this trial, the combined scores of the validated O’Leary Interstitial Cystitis 




Figure 6. Correlation between combined scores of RICAS and ICS/P  
 
In conclusion, all three radiation cystitis measurement systems, modified RTOG, ICS/P and RICAS 
failed to identify any statistically significant differences between the cranberry and placebo arms. 
This was contrary to expectations based on the previous pilot study from Hamilton et al that 
cranberry capsules were superior to placebo capsules in decreasing some cystitis symptoms such as 
pain and improve strength of flow, and using fewer pads and liners using the EPIC scoring system 
(37). 
3.6 The effect of treatment regimen on the severity of radiation cystitis. 
The trial was stratified for three different treatment regimen to account for their potentially 
different effect on radiation cystitis: 1) conventional: 74Gy in 37 fractions, 2) CHHiP trial: 60Gy in 20 
fractions, and 3) prostate bed: 66Gy in 33 fractions. The CHHiP trial regimen (85) has a higher daily 
dose per treatment and this could lead to more severe acute side effects occurring at an earlier 
stage in the treatment regime compared to conventional treatment (86). The lower total dose for 












RICAS v ICS/P Combined Scores
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For the current study, in the cranberry arms 2 patients were on the conventional regimen, 4 patients 
on the CHHiP regimen and 3 patients on the prostate bed regimen. For the placebo arms these 
numbers were 0, 7 and 3 respectively. When cystitis severity data from patients of both arms were 
combined (Table 12, Table 13, Table 14) analysis shows a significant difference between the prostate 
bed and CHHiP treatment in the ICS/P questionnaire, with prostate bed patients experiencing 
reduced urgency and frequency; otherwise there was no significant difference in the severity of 
cystitis between the prostate bed and CHHiP treatment regimen. There was no significant difference 
between the severity of cystitis between the CHHiP and conventional treatment regimen and 
conventional and prostate bed treatment regimen.  
Table 12. Average Scores each treatment regimen for modified RTOG 

















Pain 0.55 0.13 1.00 0.00 0.5 0.14 0.16 1.0 0.32 
Urgency 0.91 0.18 0.50 0.18 0.67 0.13 0.32 0.32 1.0 
Day time frequency 1.18 0.22 1.50 0.18 1.17 0.10 1.0 0.71 0.32 
Night time frequency 0.64 0.20 1.00 0.00 1 0.16 1.0 0.32 1.0 














Table 13. Average Scores each treatment regimen for ICS/P 


















How often have you experienced 
pain/burning in your bladder?  
1.09 0.38 1.50 0.18 1.67 0.49 0.18 0.19 0.32 
How often have you felt a strong 
need to urinate with little or no 
warning? 
1.82 0.35 1.50 0.18 0.5 0.14 0.32 0.04 0.16 
How often have you had to urinate 
less than 2h after you finished 
urination?  
2.09 0.21 1.00 0.35 1.17 0.25 0.18 0.04 0.32 
How many times did you typically 
have to get up in the night to 
urinate? 
1.18 0.22 1.00 0.00 1.67 0.26 0.16 0.40 0.32 
IC Problem     
Burning/pain?  
0.64 0.26 1.00 0.00 0.5 0.14 0.16 0.56 1.0 
Having to urinate with little 
warning? 
1.55 0.30 0.50 0.18 1.17 0.19 0.16 0.23 0.32 
Having to urinate again within 2 
hours? 
1.64 0.23 0.50 0.53 1.33 0.26 0.18 0.41 0.32 
Having to get up in the night to 
urinate? 
1.36 0.28 1.00 0.35 1 0.00 0.18 0.16 1.0 















Table 14. Average Scores each treatment regimen for RICAS 
Maximum-baseline scores 
















Severity        
How often do you feel pain 
and burning when urinating? 
0.82 0.27 2.00 0 1.33 0.30 0.16 0.06 0.32 
How severe is this pain 
0.73 0.23 1.50 0.18 0.67 0.13 0.18 0.32 0.16 
How often do you feel pain in 
your bladder? 
1.18 0.35 2.50 0.18 0.5 0.14 0.18 0.71 0.18 
How severe is this pain? 
0.73 0.23 1.00 0.00 0.5 0.14 0.16 1.0 0.32 
How often do you need to 
urinate during the day time 
frequency? 
1.36 0.13 1.00 0.00 1.17 0.10 0.32 0.32 1.0 
How often do you need to 
get up in the night to 
urinate? 
1.18 0.27 1.00 0.00 0.83 0.19 0.32 0.78 0.32 
How quickly do you need to 
urinate when you feel the 
urge? 
1.18 0.22 0.00 0.35 1 0.27 0.18 0.58 0.32 
How would you describe your 
bladder control? 
0.36 0.17 0.50 0.18 0.17 0.19 1.0 0.28 1.0 
How would you describe the 
strength of your flow? 
0.91 0.24 1.50 0.18 0.5 0.14 0.32 0.66 0.16 
RICAS Impact   
Frequency and severity of 
pain/burning 
0.45 0.21 0.50 0.18 0.17 0.10 0.32 0.32 0.32 
Number of times you needed 
to urinate during the day 
0.36 0.28 1.50 0.18 0.67 0.34 0.32 0.33 0.16 
Getting up at night to urinate 
0.82 0.29 0.50 0.53 0.67 0.26 0.32 1.0 0.66 
The urgency with which you 
had to urinate 
0.73 0.23 1.50 0.18 1 0.32 0.32 0.68 0.16 
The amount of control you 
had over your bladder 
0.55 0.17 0.00 0.35 0.17 0.19 0.18 0.33 1.0 
The strength of your flow 
0.73 0.25 1.50 0.18 1.17 0.25 1.0 0.23 0.16 








CHAPTER 4. Discussion  
Prostate cancer is the most common cancer for New Zealand men.  Radiation therapy is a common 
treatment option for men and acute radiation induced cystitis is an unavoidable side effect of this 
treatment. There is currently no preventative intervention for acute radiation induced cystitis only 
symptomatic control. 
4.1 The effect of cranberry capsules on the severity of radiation cystitis 
The rationale for running another acute radiation cystitis management study was the poorly 
researched performance of current interventions. The oldest study was reported in 2003 by 
Campbell et al (2003) (70). This unblinded RCT in 112 prostate cancer patients did not show a 
significant difference in urinary symptoms between patients that drank cranberry juice and those 
that drank apple juice (p=0.76). The trial was limited by a lack of blinding and poor compliance in 
drinking the juice. The double blinded RCT by Cowan et al (2012) was limited by poor recruitment 
and poor patient compliance (69). This study enrolled 128 prostate cancer patients who took either 
cranberry juice of non-cranberry placebo juice but only 32 patients drank more than 16 litres during 
the trial period. The authors reported a small non-significant difference in the incidence of urinary 
symptoms in men drinking cranberry juice (p=0.24). Neither of these trials reported on the 
proanthocyanidin (PAC)content of their cranberry juice. The most promising results to date were 
those reported by Bonetta and Pierro (2012), who  compared standardised cranberry tablets 
containing 60mg PACs with standard treatment in 370 prostate cancer patients (71). Compliance 
with taking cranberry tablets was high and cranberry tablets significantly decreased lower urinary 
tract symptoms (p<0.01). However, this study was limited by a lack of randomisation and blinding 
and standard treatment was not defined. Allocation bias and reporting bias may have contributed to 
the highly favourable outcome of this study. The NZ pilot study by Hamilton et al (2015) was a 
double blinded RCT using standardised cranberry capsules containing 72 mg of PACs and placebo 
capsules in 41 prostate cancer patients (37). Cranberry capsules decreased the severity of acute 
radiation cystitis as evidenced by a statistically significant decrease in pain/burning (p=0.038), 
stronger urine stream (p=0.030), and using significantly fewer pads (p=0.042). These encouraging 
results need to be validated in a larger clinical trial, and that is the subject of this thesis.  
Clinically significant effect size 
One could argue that a statistically significant very small decrease in cystitis symptoms may not be 
clinically significant. None of the trials described the effect size in their results. However, a re-
analysis of the results from the NZ pilot study showed that the effect size between cranberry 
capsules and placebo capsules for pain/burning, stronger urine stream and using fewer pads were 
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35%, 43% and 40% respectively, which is highly clinically significant (Dr Herst, personal 
communication 5 /08/2020). In fact, a 20% decrease in the severity of pain/burning could be 
considered clinically significant. To be able to find a statistically significant difference of 20% would 
require a much larger cohort of patients.  
 
With that in mind, the current larger 101 patient trial was designed to have a power of 79% for 
pain/burning, 88% for nocturia and 96% for strength of flow to find a significant difference (p = 
0.05), between cranberry and placebo arms (88). Contrary to expectations the analysis of the small 
thesis cohort and the larger 101 patient cohort did not find a statistically significant difference 
between cranberry and beetroot placebo capsules with respect to cystitis symptoms.  
 
This thesis discusses the trial findings for the patients at the Kathleen Kilgour Centre for this thesis 
(n=19). There was no statistically significant difference for any of the symptoms or their effect on 
day to day life in any of the three scales used between the cranberry and placebo arms. In fact, for 
some scale items cranberry capsules seem to give worse cystitis scores than placebo capsules. This 
could have been due to the small cohort and large range of values of different cystitis symptom 
items. However, it could also have been due to the higher acidity level of the cranberry capsules, 
which may have irritated the bladder lining by increasing the acidity of the urine in the bladder (87). 
Decreasing bladder acidity can be achieved by using URAL and this will result in symptom relief. 
Therefore, an increase in bladder acidity might increase the severity of cystitis symptoms. 
 
Despite the high antioxidant and anti-inflammatory properties of the cranberry capsules, measured 
by a free radical scavenging and neutrophil anti-inflammatory assay (Appendix E), this did not 
decrease cystitis symptoms in this patient cohort. It is possible that the cranberry concentration in 
the bladder was not adequate to dampen the effect of free radicals generated by radiation therapy 
or dampen the inflammatory response to reduce radiation-induced damage to the urothelium. 
However, it could also be possible that anti-oxidant activity is not a factor in protecting the bladder 
wall from radiation damage. The thesis cohort is too small to draw any firm conclusions from 
Clinical Implications 
Many radiation therapy departments, including the Kathleen Kilgour Centre, have recently promoted 
the use of cranberry capsules to their prostate cancer patients. This was due to the popular 
perception that cranberry products are good for bladder health, as well as the results from the New 
Zealand pilot study that suggest cranberry capsules may decrease symptoms of radiation cystitis. In 
light of the results of this small thesis study and the overall results of the larger 101 patient study 
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(88), we no longer give this advice and a pdf of the results of the larger study has been circulated 
amongst all New Zealand radiation therapy departments. 
4.2 Use of a novel scale to measure radiation cystitis severity 
RTOG is the scale most used by Radiation Oncologist for reporting severity of radiation induced 
cystitis, however it is not a very sensitive scale as it has only 5 different grades. The O’Leary 
Interstitial Cystitis scale is more sensitive, but it was made to report interstitial cystitis symptoms not 
radiation cystitis. Hence a new score was developed for this trial to measure the severity of acute 
cystitis caused by radiation therapy. 
RICAS is a currently unvalidated scoring system that was newly created to assess non-haemorrhagic 
radiation cystitis. Dr Herst modelled RICAS on the IC symptoms and problem scales and the EPIC 
Urinary Domain (37) in response to the cranberry pilot study in Dunedin. RICAS was specifically 
designed for prostate cancer patients undergoing radiation therapy, measuring both symptom 
severity and symptoms impact on HRQoL. Hamilton et al identified that the phrasing of several 
questions of EPIC were interpreted differently by different patients (37). RICAS was created to be 
less ambiguous and more sensitive to small changes in severity when compared to RTOG and CTCAE.  
RICAS was created to fill a gap in measurement tools by allowing a specific and sensitive tool to be 
easily utilised in clinics to assess patient’s cystitis symptoms. When comparing the items between 
RICAS and ICS/P as in Figure 11 a moderate positive correlation was evident. This was expected as 
the items between the two scales are very similar, with RICAS producing higher scores because of 
the larger number of individual items. Both RICAS and ICS/P are patient reported outcome scales 
and comparing those directly is valuable. In the future, RICAS should be validated using the limits of 
agreement approach (89).  
4.3 Strengths and Limitations  
Strengths 
Randomisation and blinding. 
Lack of randomisation and blinding are two very strong potential confounders in many clinical trials 
resulting in allocation bias and researcher/participant bias. A major strength of this trial was the fact 
that is was randomised and double blinded. Participants were randomised into either the placebo or 
the cranberry capsule arm with the men receiving unmarked bottles with cranberry and placebo 
capsules that are indistinguishable from each other. This randomisation and blinding circumvented 
the possibility of allocation bias and the placebo effect from confounding the trial. The TRT did not 
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know which arm the participant was allocated and the participants self-reported their side effects 
for RICAS and ICS/P assessments.  
Having the appropriate placebo control. 
The placebo capsules used for this study contained red beetroot powder to make them 
indistinguishable for the cranberry capsules. Beetroot contains betalains, which have anti-
inflammatory and antioxidant properties. However, these particular capsules were tested and found 
to have very low anti-inflammatory and no antioxidant activities. Therefore, these capsules were 
appropriate placebo capsules for the trial. 
Stratification for different treatment regimen. 
A lower total dose or a higher dose per fraction may affect cystitis severity. In order to circumvent 
potential confounding of unequal allocation to lower dose regimen, the trial randomisation to these 
three treatment regimens were stratified. This study found that there was no difference in cystitis 
severity between the different treatment regimens. However, considering the very low numbers in 
these different sub-cohorts, these results should be interpreted with a lot of caution. However, the 
results from the larger 101 patient study (88) as well as those by the 5 year CHHiP trial (85) that also 
reported that the distribution of the toxicities by RTOG grade was similar between both 
fractionation schedules (85).  
Bladder doses and volumes 
The smaller the volume of bladder in the treatment field, the lower the dose to the bladder, the less 
radiation damage received by the urothelium and the less severe the side effects. Bladder volume 
and dose to the bladder was determined at the time of CT and afterwards by daily cone beam CTs. 
Both bladder volume and dose of the bladder were very similar between cranberry and placebo 
cohorts and therefore unlikely to have confounded the results. 
 
Limitations 
The major limitation of this trial is the fact that the participant cohorts were very small (9 cranberry 
arm patients and 10 placebo patients) has the potential for a type II error (false negative). This 
means that the lack of efficacy of cranberry capsules may have been due to the low number of 
participants rather than a lack of effect per se. However, analysis of the larger 101 patient trial has 
shown the same lack of efficacy and therefore the results of the smaller thesis study are less likely to 
have been due to a type II error. 
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4.4 Recommendations for further research 
Further research into managing acute radiation induced cystitis is recommended. As seen in the 
literature review the research in management of acute radiation induced cystitis is not strong and 
most interventions are for symptom management as opposed to preventing damage to the bladder. 
However, the findings of this study do not support the use of cranberry products as a possible 
intervention.  
Conclusions 
Results from the small thesis cohort reject the hypothesis that cranberry capsules were superior to 
beetroot containing placebo capsules in managing acute radiation induced cystitis. Due to the small 
number of analysable patients (n=19), these results must be viewed with caution. However, this 
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Appendix C: Patient Information and Consent 
 
                
 
PARTICIPANT INFORMATION SHEET 
 
Study title: 
Determining the efficacy of cranberry capsules in the 
management of acute radiation cystitis  
Clinical Principal 
Investigator 
Dr Leanne Tyrie, Kathleen Kilgour Centre 
Academic Principal 
investigator 
Dr Patries Herst, University of Otago 
 
 















You are invited to take part in a clinical study which investigates whether taking daily 
cranberry capsules affects the severity of bladder symptoms that are often experienced by 
patients who receive radiation therapy for prostate cancer.  
This information sheet explains why we are doing this study and what you have to do to take 
part. We will go through the information sheet with you and we will answer any questions 
you may have about the study. Please discuss your participation in this trial with friends, 
family and whanau and take your time to decide whether you would like to take part in this 
study.  
Whether you decide to take your part in the study is entirely your choice. Even if you decide 
to take part now and change your mind later, you can withdraw at any time without giving a 
reason. If you decide to participate we will ask you to sign the consent form on page 8.  If 
you decide not to take part there will be no disadvantage to you and we thank you for 
considering our request. Participation in this trial will not affect any current or future 
healthcare you may receive. 
1. Why are we doing this study? 
You have been diagnosed with prostate cancer and your oncologist has recommended that 
radiation therapy is the best way to treat your prostate cancer. When your prostate gland is 
irradiated a small part of your bladder is likely to receive some radiation as well because it is 
located directly above the prostate gland (see Figure 1). This may result in bladder symptoms 
called radiation cystitis. Symptoms include: pain when urinating, pain in your lower abdomen, 
increased number of times you need to urinate (day or night), the urgency with which you 
need to urinate, bladder control (leakage), blood in the urine and urinary tract infections. You 
may have some, all or none of these symptoms and the symptoms you have may be mild, 
moderate or severe. Symptoms often occur towards the end of the second week of your 
radiation treatment and will usually disappear within 2 or 3 weeks after completion of 
radiation treatment. There is currently no treatment for these bladder symptoms. Cranberry 
products have been associated with a healthy bladder and a decrease in the number of 
urinary tract infections in young women. We are doing this study because we want to find 
out if taking daily cranberry capsules is better than taking placebo capsules in managing any 
bladder symptoms you may have. If we find that taking a simple nutritional supplement like 
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cranberry capsules makes the bladder symptoms better, this would improve the wellbeing of 





This study compares the effect of taking daily cranberry capsules with that of placebo 
capsules on the severity of radiation cystitis in men receiving radiation therapy for 
prostate cancer. 
. 
2. Who is funding the study? 
The study is funded through a University of Otago Research Grant.  
 
3. Who will be recruited for this study? 
All men who come to the department to receive radiation therapy for prostate cancer will be 
approached with information about the trial by the radiation oncologist. However men who 
have had previous radiation therapy to the lower abdomen, who have metastatic disease, a 
history of kidney stones, take blood thinners or who are allergic to cranberry products will not 
be able to participate in the trial.  
 
Figure 1. The prostate gland is 
directly underneath the bladder. 
Bladder 
Prostate gland 
Tube that empties 





4. What does my participation in the study involve? 
A. Randomisation 
Once you have been accepted into the trial you will be randomly placed in either the cranberry 
or in the control arm. Randomisation is done using a computer programme and cannot be 
influenced by the oncologist, the research assistant or yourself. You, your doctor or the 
research assistant will not know which arm you have been placed in. You will have a 50% 
chance of receiving cranberry capsules and a 50% chance of receiving placebo capsules. 
 
Why randomisation?  
Generally people feel better when they get capsules that they think will make them better, 
even if these are fake capsules. This is called the “placebo effect”. In this trial we give people 
in the control arm placebo (fake) capsules to measure this placebo effect. We give people in 
the cranberry arm the real cranberry capsules to measure the real effect of cranberries over 
and above the placebo effect. Randomisation is much more effective if the participants, their 
clinicians and radiation therapists do not know whether they are taking cranberry capsules or 
placebo (fake) capsules. This is called blinding the trial. 
 
B. Protocol 
 Regardless of the arm you are placed in, you will be given a bottle containing 140 capsules.  
 You need to take 2 capsules each day when you wake up from the day you start radiation 
treatment until you have used up all the capsules (10 weeks later).  
 You may take ural sachets or any other medication as recommended by the treating 
physician 
 You are not allowed to take foods, drinks or supplements containing cranberries, blueberries 





You will be asked to fill in three short questionnaires before you start radiation treatment and 
then every week for 10 weeks. Together, these questionnaires will take about 20 minutes to 
fill in and will ask you to comment on your urinary habits, and stress levels of the previous 
week, including frequency, urgency and discomfort and how much these symptoms have 
affected your day to day life. 
 
 
5. Are there any risks to me if I participate in this study? 
 These cranberry capsules can be bought over the counter and in supermarkets as 
nutritional supplements and are very unlikely to cause any side effects. 
 
 In the unlikely event of an adverse reaction to either type of capsule we will ask you to 
stop using the capsules. 
 
6. Compensation 
In the unlikely event of a physical injury as a result of your participation in this study, you may 
be covered by ACC under the Accident Compensation Act 2001. ACC cover is not automatic, 
and your case will need to be assessed by ACC according to the provisions of the Accident 
Compensation Act 2001. If your claim is accepted by ACC, you still might not get any 
compensation. This depends on a number of factors, such as whether you are an earner or 
non-earner. ACC usually provides only partial reimbursement of costs and expenses, and 
there may be no lump sum compensation payable. There is no cover for mental injury unless 
it is a result of physical injury. If you have ACC cover, generally this will affect your right to sue 
the investigators.  
If you have any questions about ACC, contact your nearest ACC office or the investigator.  
 
You are also advised to check whether participation in this study would affect any indemnity 






7. Are there any costs involved if I participate in this study? 
There are no costs to you for participating in this study. Neither will you be paid for taking 
part in the study. 
 
 
8. What will you do with the information? 
Information that may identify you, such as your name, address and date of birth, will be kept 
together with your medical records and cystitis symptom scores in your patient file at the Kathleen 
Kilgour Centre.  
 
The Academic Principal Investigator, Dr Patries Herst who will collate and analyse all the 
information, will receive your information in a form that is no longer linked to your name, address or 
date of birth. You will be given a special trial number to which all the trial information is linked.    
 
This de-identified information will be stored in in lockable metal filing cabinet in the office of the 
Principal Investigator, at the University of Otago, Wellington for a period of 10 years. Only the 
research radiation therapist will be able to link the de-identified data to the patient files.  
 
When the study is completed the information from all the participants of the study will be 
collated and analysed. This will tell us whether cranberry capsules are better than placebo 
capsules in preventing bladder symptoms.  
 
Reporting 
 We will report on the results of this study in scientific publications and conference 
presentations.  
 You will be sent a summary of the study results if you so wish. 
 





9. Do I have to participate in this study? 
No, there is absolutely no requirement to participate in the study.  
 
 
10. Can I withdraw from the study if I change my mind? 
If you do agree to take part, you are free to withdraw from the study at any time, without 
having to give a reason and this will in no way affect your current or future health care. 
 
If you wish to withdraw please advise a member of your medical team that you have decided 
to withdraw so that all data that have not been anonymised and processed will be deleted 
from the database.  
 
 
11. What if I have more questions or concerns about this study? 
If you have any questions or concerns about your rights as a participant in this research 
study you can contact an independent health and disability advocate. This is a free service 
provided under the Health and Disability Commissioner Act. Local (03) 479 0265; 
Telephone: (NZ wide) 0800 555 050; Free Fax (NZ wide):  0800 2787 7678 (0800 2 
SUPPORT); Email (NZ wide): advocacy@hdc.org.nz. If there is a specific Māori 












If you have any questions or concerns about your bladder symptoms or any other 
aspects of this study, at any time, please call any of the numbers below, or email.  
 
Dr Leanne Tyrie 
Clinical Principal 
Investigator 
























Determining the efficacy of cranberry capsules in the 
management of acute radiation cystitis  
Clinical Principal 
Investigator 
Dr Leanne Tyrie, Kathleen Kilgour Centre 
Academic Principal 
investigator 
Dr Patries Herst, University of Otago 
 
 
Lay title: Cranberries for radiation cystitis 
 
 
CONSENT FORM FOR PARTICIPANTS 
 
This form is to obtain your agreement to participate in our study which intends to find out 
whether cranberry capsules decrease the severity of cystitis caused by radiation therapy 
treatment.  
 
Following signature and return to the research team this form will be stored in a secure place 




 I have read and I understand the information sheet dated April 2016 concerning this 
study and understand the aims of the study.  
 I have had sufficient time to discuss this study with whanau and friends about my 
choice of taking part in this study. 
 I confirm that I meet the criteria for participation which are explained in the 
information sheet. 
 I understand that taking part in this study is voluntary (my choice), and that I may 
withdraw from the study at any time, and this will in no way affect my current and 
future health care. 
 I understand that my participation in this study is confidential and that no material that 
could identify me will be used in any reports on this study. 
 All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
 I know who to contact if I have any questions about my participation in this study or 
about the study in general. 
 I know that as a participant I will 
o Be randomised to either the cranberry or placebo arm. 
o Take two capsules each day when I wake up from the start of radiation 
therapy treatment until all the capsules have been finished. 
o Fill in three questionnaires about any urinary symptoms and stress levels I 
may have before I start radiation treatment and once a week for ten weeks 
after that. I know I may decline to answer any particular question(s)  
 I understand the nature and size of the risks of discomfort or harm which are explained in 
the Information Sheet. 
 I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from the 
project, and that these will be placed in secure storage and kept for at least ten years.  
 I understand that the results of the project may be published, but that I agree that any 
personal identifying information will remain confidential between myself and the 
researchers during the study, and will not appear in any spoken or written report of the 
study  
 I know that there is no remuneration offered for this study, and that no commercial use will 









I consider my ethnicity to be: 
 
O New Zealand European 
O Mäori  
O Samoan 





O Other (such as Dutch, Japanese, Tokelauan). Please state. 
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I,  ………………………………………………. (full name) hereby consent to take part in this 






Full names of researchers:  
  




Project explained by:  
  



















Appendix D: Cone Beam CT Bladder Filling Data 

















1 365.3 479.1 429.5 275.5 234.5 273.8 327.7 
2 38.2 452.6 112.1 309.1 396.2 151 144.7 
3 279.6 439.3 181.4 171.9 121 117.6 165.2 
4 162.8 300 192.6 225.3 424.8 244.2 176.2 
5 116.7 405.4 332.5 224 167.2 207 392 
6 99.7 160.5 154.8 97.1 360.6 212.4 429.2 
7 93.4 290.9 409.1 295.9 336.3 170.8 216.1 
8 308.5 284.8 300.5 320 313.7 103.4 105.5 
9 174.7 376.7 412.4 409.5 267.7 325 202.9 
10 71.9 80 275 269 354 227.8 221.3 
11 73.5 273.1 405.6 395.4 169.6 428.3 175.4 
12 167.9 198 135.7 218 338.1 330.7 143.8 
13 367.4 188.5 361.9 162.9 323.4 323.8 107.5 
14 343.1 357.3 209.5 391.4 279.8 185 379.7 
15 247.8 203.1 262.4 259 267.4 187.5 129.9 
16 326.4 179.3 366.8 310.6 328.1 201.8 359.6 
17 131.5 315.1 168.8 305 185.7 149.7 148 
18 83.9 423.4 208.1 322.1 276.3 182.9 161.4 
19 86 399.3 186.6 338 151.1 256.2 118.3 
20 45.6 303.8 305 230.2 335.9 171.8 123.2 
21 233.6   224.4 340.2   185.1   
22 174.6   280 240.2   202.8   
23 105.2   285.5 306.2   Missing data   
24 80.2   198.7 301.1   Missing data   
25 158.9   275.2 332.8   Missing data   
26 118.1   124 154.7   Missing data   
27 188.4   234.2 274.2    Missing data   
28 96   325.3 215.5   170.7   
29 135.1   206.6 132.7   291   
30 74.9   153.4 263.5   176.1   
31 153.3   342.5 149.8   272.5   
32 104.7   282.6 284.6   157.1   
33 246.4   262 267.2   166.0   
34    308.8         
35     347.5         
36     291.2         
37     343.5         
Average 
bladder 






















1 343.3 269 123.5 177.9 230.5 214.4 306.3 
2 344.9 410 123.4 200 149 522.4 198.2 
3 414.8 143.4 154.3 107.5 100.4 131.5 134.2 
4 446.3 414.6 117 208.4 175.3 532.1 203.5 
5 425.2 286.7 179.9 84 89.7 244.9 56.4 
6 443.1 274.7 196.1 178.1 188.8 346.2 92 
7 389.9 241.1 175.6 230.8 98.6 445 117.9 
8 462.6 285 201.7 91.7 193.9 340.9 106.3 
9 397.4 135.6 120.3 97.9 117.9 313.7 123.7 
10 392.1 282.2 224 120.3 133.2 499.4 116 
11 392.4 300.7 106 174.8 217 367.9 35.8 
12 369.7 197 125.6 173.2 161.1 337.2 190.6 
13 437.6 245.1 184.7 195.7 194.3 386.2 Missing data 
14 404.8 190.2 94.7 159.5 169.2 107.5 285.4 
15 361.5 209 101 148.4 95.2 258.6 155.4 
16 423.7 124.7 109.1 206.4 189.7 139.7 300.1 
17 391.5 321.7 172.2 76.9 119.3 227.8 190.4 
18 355.4 313.4 102.7 116.6 203.3 227.1 139.3 
19 397 222 106.1 Missing data 162.1 210 149.3 
20 356.8 203.7 71.2 Missing data  167.3 174.1 122.6 
21     105.2     192.1 155.1 
22     93.8     139.2 154.6 
23     107.4     235.2 132.1 
24     166     364.9 125 
25     93.4     160.4 142.8 
26     83     221.1 136.4 
27     188.3     234.7 155.5 
28     96.1     346.6 130.7 
29     178.9     121.9 266.7 
30     115.3     339.3 224.1 
31     107.7     125.3 445.4 
32     88.3     310.3 155.7 
33     160.1     174.0 64.7 
34     127.6         
35     145.2         
36     274.2         




 397.5 253.5 136.4 152.7 157.8 272.5 166.0 
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1 76.3 184 114.4 184.6 513.1 
2 178.4 221.6 169.3 233.1 512 
3 274.8 390.9 103 142.4 425.5 
4 160.8 434.7 251.1 Missing Data 300.6 
5 124.5 305.2 337.9 243.3 184.6 
6 313.2 259.8 293.5 167.3 171.2 
7 181.1 264 225.3 169.9 317 
8 255.7 242.5 271.8 243.1 311.5 
9 252.3 342.7 167.4 266.6 321.2 
10 159 264.4 132.9 221.7 231.8 
11 132.6 264.5 169.5 105.9 256.5 
12 177.2 182.4 214 186.8 277.5 
13 216.7 196.6 164.9 151.8 114 
14 137.6 229.2 254 190.4 192.2 
15 91.8 218.2 141.9 203.5 276.3 
16 175 226.4 202.1 150.5 227.4 
17 172.9 236.6 301 256.9 132.9 
18 95.4 203.8 197.6 164.3 Missing data 
19 189.4 235.2 267.4 187.4 296.1 
20 101.5 124.8 152.5 222 174.8 
21 106.9         
22 256.5         
23 237.3         
24 248.5         
25 174.7         
26 89.2         
27 169.2         
28 210.1         
29 187.1         
30 100.9         
31 182.1         
32 103.6         
33 276.2         
34           
35           
36           
37           
Average 
bladder size 





Appendix E: Antioxidant and Anti-Inflammatory capacity of cranberry and placebo 
capsules 
 
Anti-inflammatory assay: inhibition of neutrophil superoxide production  
 
This assay measures superoxide levels in stimulated dHL60 neutrophil cultures exposed to the 
cranberry and placebo capsule extract. In the presence of a stimulant, neutrophils swiftly produce a 
respiratory burst; a rapid but brief production and release of superoxide. Inhibition of the 
respiratory burst is a measure of anti-inflammatory capacity. 
 
 
Anti-oxidant activity: inhibition of superoxide production by xanthine oxidase  
 
This assay measures the ability to directly neutralize the superoxide produced in a cell free enzyme 
assay. The enzyme xanthine oxidase oxidizes xanthine to uric acid which produces superoxide. 




Cranberry capsule extract has both anti-inflammatory (IC50 = 5.5 µg/mL; R2= 0.969) and anti-oxidant 
(free radical scavenging) activities (IC50 =57.5 µg/mL; R2= 0.957). Beetroot placebo capsule extract 
had much lower anti-inflammatory activity (IC50 = 99.0 µg/mL; R2= 0.911) and no antioxidant activity 
(IC50>1000 µg/mL; R2= 0.382). 
 
Table 1. Results of anti-inflammatory and anti-oxidant assays. 
 Anti-inflammatory activity Anti-oxidant activity 
Cranberry capsule extract IC50 = 5.5 µg/mL; R2= 0.969 IC50 =57.5 µg/mL; R2= 0.957 




Three cranberry capsules were each dissolved in 1 L deionized water and the acidity measured with 
a pH meter. This cranberry solution was very acidic with a pH of 3.9 ± 0.2. Beetroot capsule extracts 
were much more neutral with a pH of 6.3 ± 0.3. 
 
 
